AMSTERDAM – Use of a Royal Philips noninvasive ventilation (NIV) device at home can save millions in readmission costs and reduced hospitalization rates for patients with severe chronic obstructive pulmonary disease (COPD), a recent study has found.
The Philips-sponsored study assessed whether a comprehensive strategy of care, including the use of the Philips Trilogy 100 NIV, can reduce the economic burden of managing patients with moderate to severe COPD.
“The study shows that there are actually significant economic advantages to continuing care at home for patients who require frequent hospitalizations for COPD exacerbations,” said Dr. Teofilo Lee-Chiong, chief medical liaison at Philips. “Hospital admissions and readmissions for worsening COPD account for a large portion of health care expenditure. The latter affects the patients, hospitals and payers alike.”
Conducted at Barnes Healthcare Services, the study’s at-home program of care included advanced NIV therapy with the Trilogy, oxygen therapy, respiratory therapist-led care, patient education and medication reconciliation. It found that the reduction in readmissions led to a cumulative hospital savings of more than $400,000 over 30 days. After examining 1,000 COPD patients being treated with the combined treatment method, hospitals saved $1.6 million in the first 30 days, compared to no NIV treatment or less advanced NIV therapy devices. Payers had a cumulative 3-year savings of $326 million when using home NIV in comparison to no NIV treatment.
Lee-Chiong said NIV assists patients with breathing by providing a prescribed volume of air during inspiration. Newer technologies, like the Philips Trilogy, continuously adjust the delivered pressure to reach clinically desired targets and synchronize with the patient’s patterns of breathing.
The NIV model used in the study can be easily adopted by other health care providers, facilities and payers, said Lee-Chiong.
“As health systems continue to promote value-based care, it is increasingly important to demonstrate that programs like these can reduce costs while improving patient experiences,” he said.